ViiV Healthcare this week announced new collaborations with the goal of increasing access
to its HIV medicine, dolutegravir (marketed under the name Tivicay®),
just two months after its approval by the European Medicines Agency
(EMA) and eight months after approval by the US Food and Drug
Administration (FDA).





